PMID- 35820898 OWN - NLM STAT- MEDLINE DCOM- 20220714 LR - 20220801 IS - 1471-2431 (Electronic) IS - 1471-2431 (Linking) VI - 22 IP - 1 DP - 2022 Jul 11 TI - MYCN protein stability is a better prognostic indicator in neuroblastoma. PG - 404 LID - 10.1186/s12887-022-03449-1 [doi] LID - 404 AB - OBJECTIVE: MYCN oncogene amplification is associated with treatment failure and poor prognosis in neuroblastoma. To date, most detection methods of MYCN focus on DNA copy numbers instead of protein expression, which is the real one performing biological function, for poor antibodies. The current investigation was to explore a fast and reliable way to detect MYCN protein expression and evaluate its performance in predicting prognosis. METHODS: Several MYCN antibodies were used to detect MYCN protein expression by immunohistochemistry (IHC), and one was chosen for further study. We correlated the IHC results of MYCN from 53 patients with MYCN fluorescence in situ hybridization (FISH) and identified the sensitivity and specificity of IHC. The relationship between patient prognosis and MYCN protein expression was detected from this foundation. RESULTS: MYCN amplification status detected by FISH was most valuable for INSS stage 3 patients. In the cohort of 53 samples, IHC test demonstrated 80.0-85.7% concordance with FISH results. Further analyzing those cases with inconsistent results, we found that patients with MYCN amplification but low protein expression tumors always had a favorable prognosis. In contrast, if patients with MYCN non-amplified tumors were positive for MYCN protein, they had a poor prognosis. CONCLUSION: MYCN protein level is better than MYCN amplification status in predicting the prognosis of neuroblastoma patients. Joint of FISH and IHC could confirm MYCN protein stability and achieve better prediction effect than the singular method. CI - (c) 2022. The Author(s). FAU - Yang, Yi AU - Yang Y AD - Pediatric Translational Medicine Institute, Department of Hematology & Oncology, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, National Health Committee Key Laboratory of Pediatric Hematology & Oncology, Shanghai, 200127, China. FAU - Zhao, Jie AU - Zhao J AD - Department of Hematology & Oncology, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, National Health Committee Key Laboratory of Pediatric Hematology & Oncology, Shanghai, 200127, China. FAU - Zhang, Yingwen AU - Zhang Y AD - Pediatric Translational Medicine Institute, Department of Hematology & Oncology, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, National Health Committee Key Laboratory of Pediatric Hematology & Oncology, Shanghai, 200127, China. FAU - Feng, Tianyue AU - Feng T AD - Pediatric Translational Medicine Institute, Department of Hematology & Oncology, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, National Health Committee Key Laboratory of Pediatric Hematology & Oncology, Shanghai, 200127, China. AD - Gezhi Senior High School of Shanghai China, Shanghai, 200001, China. FAU - Yv, Bo AU - Yv B AD - State Key Laboratory of Oncogenes and Related Genes, Renji-Med X Clinical Stem Cell Research Center, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, China. FAU - Wang, Jing AU - Wang J AD - Department of general Surgery/Surgical Oncology Center, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China. FAU - Gao, Yijin AU - Gao Y AD - Department of Hematology & Oncology, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, National Health Committee Key Laboratory of Pediatric Hematology & Oncology, Shanghai, 200127, China. gaoyijin@scmc.com.cn. FAU - Yin, Minzhi AU - Yin M AD - Department of Pathology, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China. yinminzhi@scmc.com.cn. FAU - Tang, Jingyan AU - Tang J AD - Department of Hematology & Oncology, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, National Health Committee Key Laboratory of Pediatric Hematology & Oncology, Shanghai, 200127, China. tangjingyan@scmc.com.cn. FAU - Li, Yanxin AU - Li Y AD - Pediatric Translational Medicine Institute, Department of Hematology & Oncology, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, National Health Committee Key Laboratory of Pediatric Hematology & Oncology, Shanghai, 200127, China. liyanxin@scmc.com.cn. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220711 PL - England TA - BMC Pediatr JT - BMC pediatrics JID - 100967804 RN - 0 (MYCN protein, human) RN - 0 (N-Myc Proto-Oncogene Protein) SB - IM MH - Gene Amplification MH - Humans MH - In Situ Hybridization, Fluorescence MH - *N-Myc Proto-Oncogene Protein/genetics/metabolism MH - *Neuroblastoma/diagnosis/genetics/metabolism MH - Prognosis MH - Protein Stability PMC - PMC9277955 OTO - NOTNLM OT - FISH OT - IHC OT - MYCN OT - Neuroblastoma OT - Protein stability COIS- The authors declare no conflicts of interest EDAT- 2022/07/13 06:00 MHDA- 2022/07/15 06:00 PMCR- 2022/07/11 CRDT- 2022/07/12 23:38 PHST- 2022/01/09 00:00 [received] PHST- 2022/06/23 00:00 [accepted] PHST- 2022/07/12 23:38 [entrez] PHST- 2022/07/13 06:00 [pubmed] PHST- 2022/07/15 06:00 [medline] PHST- 2022/07/11 00:00 [pmc-release] AID - 10.1186/s12887-022-03449-1 [pii] AID - 3449 [pii] AID - 10.1186/s12887-022-03449-1 [doi] PST - epublish SO - BMC Pediatr. 2022 Jul 11;22(1):404. doi: 10.1186/s12887-022-03449-1.